Sermorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
Sermorelin is GHRH(1-29) — the working business end of your own growth-hormone-releasing hormone. Researchers found that the first 29 of GHRH’s 44 amino acids carry the full GH-releasing activity, so sermorelin is that fragment, synthesized. It binds your pituitary’s GHRH receptor and triggers a normal, pulsatile GH release.
The key idea: sermorelin doesn’t give you growth hormone. It asks your pituitary to make its own. That’s the physiologic way to do it — your body keeps the dimmer switch (somatostatin feedback) so the system self-regulates, releasing GH in the natural pulses it’s built around rather than the non-pulsatile flood of injected HGH. Among the GHRH family, sermorelin is the short, gentle, most-natural-mimicking member: compare it to CJC-1295 with-DAC (engineered for a multi-day half-life) or Tesamorelin (the FDA-approved, longer-acting GHRH cousin).
And here’s what sets sermorelin apart from everything else in this GH-axis set: it was once a real, fully FDA-approved drug, with a clinical dossier behind it. That gives it a more legitimate paper trail than most peptides in this space.
What does it do in my body?
Natural GHRH is a 44-amino-acid hormone your hypothalamus releases to tell your pituitary, “release a GH pulse.” The active core lives in the first 29 amino acids — so sermorelin is GHRH(1-29). It binds the GHRH receptor on the anterior pituitary, triggers the standard cascade (calcium influx, cyclic-AMP), and the pituitary releases GH in a pulse.
Two features make it elegant. First, because it works upstream, your negative-feedback loop stays intact — somatostatin (your body’s GH brake) is still in play, so you get physiologic pulses rather than a flooded system. Second, its half-life is only ~10–12 minutes, so the signal is a quick tap, not a sustained shove. That short action is exactly why it’s dosed at night — to ride and amplify your natural overnight GH pulse, which is when most of your GH is released anyway.
How can it help me?
The original GHRH peptide — the first 29 amino acids of your own growth-hormone-releasing hormone, and the only peptide in this GH-axis set that was once a fully FDA-approved drug. The gentlest, most physiologic way to ask your pituitary to make its own GH. Backed by real human RCT data.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
In the pediatric trials and the long Geref track record, sermorelin was well tolerated — which is a meaningful real-world dataset most peptides don’t have.
What’s reported: injection-site reactions, facial flushing, headache, occasional nausea or dizziness — generally mild and self-limiting. Nearly all treated children developed anti-GHRH antibodies, which resolved after stopping and didn’t appear to impair growth; their long-term significance in adults is simply unstudied.
One preclinical signal worth knowing about, in context: a 2022 in-vitro and mouse-xenograft study found GHRH could transform non-tumor prostate epithelial cells and drive tumor formation in mice — a theoretical prostate signal for GHRH agonists as a class. Keep this in proportion: it’s a cell-and-mouse finding at doses and contexts that differ from therapeutic use, with no human clinical confirmation. It’s reasonable to fold routine prostate monitoring into a longer-term protocol for older men (sensible regardless of peptides), and active cancer is the standard conservative contraindication. Worth knowing, not worth alarm.
The broader GH-axis frame: as with the other secretagogues, keep IGF-1 in your age-adjusted physiologic range and check it periodically on longer runs. Sermorelin’s upstream, pulse-preserving mechanism — your somatostatin brake stays intact — is exactly why this category is considered more physiologic than exogenous HGH. And as Bakri and one practitioner both emphasize, the dominant real-world variable for any peptide is sourcing quality, not the molecule.
Regulatory status: Here’s the honest history. Sermorelin was FDA-approved as Geref in 1997 for diagnosing and treating pediatric GH deficiency. The manufacturer (EMD Serono) notified the FDA in December 2008 that Geref was being discontinued: for commercial reasons, not safety. The FDA later formally confirmed this: in a 2013 Federal Register determination it found that Geref injection “was not withdrawn from sale for reasons of safety or effectiveness”. That distinction matters: it wasn’t pulled for harming anyone. The consequence is that today there’s no FDA-approved sermorelin product; what’s sold is compounded or research-grade, used off-label, and WADA-prohibited in sport.
Part 1 — How to reconstitute it
What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.
The exact bacteriostatic-water volume and resulting concentration for Sermorelin are covered in the dosing notes and the deeper-science view. The right volume depends on the vial size.
How it's mixed
- The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
- It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
- The reconstituted vial is stored refrigerated and out of light.
- Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.
The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.
Part 2 — Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.
This is the protocol the community and practitioners use, alongside the trial-derived pediatric dose for reference.
Standard adult protocol:
- Dose: roughly 200–300 mcg subcutaneously, nightly, on an empty stomach
- Schedule: ~5 nights/week, cycled
- Reconstitution: a 5 mg vial + 2.5 ml bacteriostatic water = 2,000 mcg/ml. A 300 mcg dose = 0.15 ml = 15 units on a U-100 insulin syringe. Always confirm your vial size and target dose before drawing.
- Reference (trial dose): the pediatric trial dose was 30 µg/kg subcutaneously at bedtime.
Timing: Dose at night, fasted. Sermorelin’s ~10–12-minute half-life is the reason — you want the GH pulse to land on top of your natural overnight surge, and food (especially carbs/fat) near the dose blunts the GH response.
Cycling: Community default is cycled blocks (e.g., ~5 nights/week, with periodic breaks) to keep the GHRH receptor responsive — consistent with the general GH-axis cycling principle of not running these signals continuously indefinitely.
What should I avoid combining — and what's synergistic?
⚠️ If you’re stacking with a GLP-1 receptor agonist (Retatrutide, Semaglutide, Tirzepatide), the standard “2 hours after eating” rule isn’t long enough. GLP-1 activity slows gastric emptying — food sits in the stomach for ~3 hours rather than 2. Residual insulin from dinner suppresses the GH pulse at the pituitary, so the “dinner at 7, pin at 9” convention fails on a GLP-1. Move sermorelin to first thing in the morning when on a GLP-1, and eat 30-60 min after injection. Full rule + sources in Retatrutide § Stacking.
Stacking: Sermorelin is often run alone as the gentlest GHRH option, or paired with a ghrelin-receptor agonist like Ipamorelin on the same dual-receptor logic that drives the CJC-1295 / Ipamorelin blend (GHRH signal + ghrelin pulse = bigger combined GH release). For a longer-acting GHRH baseline, people step up to CJC-1295 with-DAC instead.
Where do people source this?
A physician-prescribed route exists for Sermorelin. Sermorelin (injection or tablet) is available through licensed US telehealth providers: an online intake, review by a licensed physician, and — if prescribed — compounding at a licensed 503A/503B pharmacy with delivery to the door. See the prescribed Sermorelin option →
OHM does not sell or handle any compound. Research-use-only material is also sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. Whatever the route, the supply chain is the real risk: only consider sources that publish batch-level third-party Certificates of Analysis.
The original GHRH peptide — the first 29 amino acids of your own growth-hormone-releasing hormone, and the only peptide in this GH-axis set that was once a fully FDA-approved drug. The gentlest, most physiologic way to ask your pituitary to make its own GH. Backed by real human RCT data.
| Class | Growth-hormone-releasing hormone (GHRH) analog — the active first 29 amino acids of natural GHRH |
| Mechanism (one-liner) | Flips your pituitary’s natural GHRH switch so you make GH in normal pulses — never injects GH directly |
| Route | Subcutaneous injection, usually at bedtime |
| Half-life | ~10–12 minutes — very short, which is the whole point |
| Evidence | Pediatric GH-deficiency RCTs [PMIDs 8329830, 8329826]; large open-label trials [PMID 8772599]; FDA-approval dossier; adult use extrapolated |
| Regulatory status | Formerly FDA-approved (Geref, 1997); voluntarily discontinued ~2008 for commercial reasons. Now compounded/RUO. WADA-prohibited. |
| Primary OHM use case | The “make-your-own-GH” peptide for sleep, recovery, and anti-aging — the most physiologic GHRH option |
What it is
Sermorelin is GHRH(1-29) — the working business end of your own growth-hormone-releasing hormone. Researchers found that the first 29 of GHRH’s 44 amino acids carry the full GH-releasing activity, so sermorelin is that fragment, synthesized. It binds your pituitary’s GHRH receptor and triggers a normal, pulsatile GH release.
The key idea: sermorelin doesn’t give you growth hormone. It asks your pituitary to make its own. That’s the physiologic way to do it — your body keeps the dimmer switch (somatostatin feedback) so the system self-regulates, releasing GH in the natural pulses it’s built around rather than the non-pulsatile flood of injected HGH. Among the GHRH family, sermorelin is the short, gentle, most-natural-mimicking member: compare it to CJC-1295 with-DAC (engineered for a multi-day half-life) or Tesamorelin (the FDA-approved, longer-acting GHRH cousin).
And here’s what sets sermorelin apart from everything else in this GH-axis set: it was once a real, fully FDA-approved drug, with a clinical dossier behind it. That gives it a more legitimate paper trail than most peptides in this space.
How it works
Natural GHRH is a 44-amino-acid hormone your hypothalamus releases to tell your pituitary, “release a GH pulse.” The active core lives in the first 29 amino acids — so sermorelin is GHRH(1-29). It binds the GHRH receptor on the anterior pituitary, triggers the standard cascade (calcium influx, cyclic-AMP), and the pituitary releases GH in a pulse.
Two features make it elegant. First, because it works upstream, your negative-feedback loop stays intact — somatostatin (your body’s GH brake) is still in play, so you get physiologic pulses rather than a flooded system. Second, its half-life is only ~10–12 minutes, so the signal is a quick tap, not a sustained shove. That short action is exactly why it’s dosed at night — to ride and amplify your natural overnight GH pulse, which is when most of your GH is released anyway.
What the research shows
Sermorelin actually has genuine human RCT data — more than most peptides in this category. Here’s the full picture, every tier labeled, strongest first.
Pediatric GH deficiency: the strongest evidence. Two randomized controlled trials [PMIDs 8329830, 8329826] plus large open-label multicenter trials [PMIDs 8772599, 18031173] show sermorelin meaningfully increased height velocity in GH-deficient children. In the Geref International study, height velocity roughly doubled (e.g., 4.1 → 8.0 cm/yr). It produced less growth than direct GH (somatropin) but clearly outperformed no treatment. This is FDA-dossier-grade human evidence that the molecule does what it’s designed to do: drive real, measurable GH-dependent outcomes in people.
Diagnostic use. Sermorelin as a GH-stimulation test is well-characterized in humans going back to the 1980s [PMIDs 18031173, 2863206] — more confirmation the GHRH-receptor mechanism reliably releases GH in people.
Adult GH-axis use. The best adult human data is a retrospective chart review of 14 hypogonadal men in which sermorelin (given alongside GHRP-2 and GHRP-6) raised IGF-1 [PMID 28830317]. Because it was co-administered, you can’t fully isolate sermorelin’s solo contribution — but it’s consistent with the mechanism. Adult body-composition, sleep, energy, and anti-aging outcomes are extrapolated from the pediatric RCT data, the diagnostic human data, and GH/IGF-1 physiology rather than from a dedicated adult RCT. A 2020 review of GH secretagogues in hypogonadal men frames the adult evidence base as still developing.
The honest map: sermorelin has real human RCT proof that it works (in growth-deficient kids), a long real-world safety track record from its Geref years, and an adult anti-aging case that’s mechanistically sound and extrapolated rather than separately RCT-proven. The adult body-comp logic doesn’t float free, though — it rests on verified GH-replacement evidence: Rudman’s landmark 1990 NEJM RCT (GH in older men improved lean mass, reduced fat, raised skin/bone density) and Brioche 2014 (GH prevents sarcopenia + mitochondrial biogenesis in aged rats). Sermorelin’s job is to raise your own GH toward that physiologic range. For a GH-axis peptide, that’s a strong evidence position — among the strongest in this set.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
This is the protocol the community and practitioners use, alongside the trial-derived pediatric dose for reference.
Standard adult protocol:
- Dose: roughly 200–300 mcg subcutaneously, nightly, on an empty stomach
- Schedule: ~5 nights/week, cycled
- Reconstitution: a 5 mg vial + 2.5 ml bacteriostatic water = 2,000 mcg/ml. A 300 mcg dose = 0.15 ml = 15 units on a U-100 insulin syringe. Always confirm your vial size and target dose before drawing.
- Reference (trial dose): the pediatric trial dose was 30 µg/kg subcutaneously at bedtime.
Timing: Dose at night, fasted. Sermorelin’s ~10–12-minute half-life is the reason — you want the GH pulse to land on top of your natural overnight surge, and food (especially carbs/fat) near the dose blunts the GH response.
⚠️ If you’re stacking with a GLP-1 receptor agonist (Retatrutide, Semaglutide, Tirzepatide), the standard “2 hours after eating” rule isn’t long enough. GLP-1 activity slows gastric emptying — food sits in the stomach for ~3 hours rather than 2. Residual insulin from dinner suppresses the GH pulse at the pituitary, so the “dinner at 7, pin at 9” convention fails on a GLP-1. Move sermorelin to first thing in the morning when on a GLP-1, and eat 30-60 min after injection. Full rule + sources in Retatrutide § Stacking.
Stacking: Sermorelin is often run alone as the gentlest GHRH option, or paired with a ghrelin-receptor agonist like Ipamorelin on the same dual-receptor logic that drives the CJC-1295 / Ipamorelin blend (GHRH signal + ghrelin pulse = bigger combined GH release). For a longer-acting GHRH baseline, people step up to CJC-1295 with-DAC instead.
Cycling: Community default is cycled blocks (e.g., ~5 nights/week, with periodic breaks) to keep the GHRH receptor responsive — consistent with the general GH-axis cycling principle of not running these signals continuously indefinitely.
Side effects & management
In the pediatric trials and the long Geref track record, sermorelin was well tolerated — which is a meaningful real-world dataset most peptides don’t have.
What’s reported: injection-site reactions, facial flushing, headache, occasional nausea or dizziness — generally mild and self-limiting. Nearly all treated children developed anti-GHRH antibodies, which resolved after stopping and didn’t appear to impair growth; their long-term significance in adults is simply unstudied.
One preclinical signal worth knowing about, in context: a 2022 in-vitro and mouse-xenograft study found GHRH could transform non-tumor prostate epithelial cells and drive tumor formation in mice — a theoretical prostate signal for GHRH agonists as a class. Keep this in proportion: it’s a cell-and-mouse finding at doses and contexts that differ from therapeutic use, with no human clinical confirmation. It’s reasonable to fold routine prostate monitoring into a longer-term protocol for older men (sensible regardless of peptides), and active cancer is the standard conservative contraindication. Worth knowing, not worth alarm.
The broader GH-axis frame: as with the other secretagogues, keep IGF-1 in your age-adjusted physiologic range and check it periodically on longer runs. Sermorelin’s upstream, pulse-preserving mechanism — your somatostatin brake stays intact — is exactly why this category is considered more physiologic than exogenous HGH. And as Bakri and one practitioner both emphasize, the dominant real-world variable for any peptide is sourcing quality, not the molecule.
Regulatory status
Here’s the honest history. Sermorelin was FDA-approved as Geref in 1997 for diagnosing and treating pediatric GH deficiency. The manufacturer (EMD Serono) notified the FDA in December 2008 that Geref was being discontinued: for commercial reasons, not safety. The FDA later formally confirmed this: in a 2013 Federal Register determination it found that Geref injection “was not withdrawn from sale for reasons of safety or effectiveness”. That distinction matters: it wasn’t pulled for harming anyone. The consequence is that today there’s no FDA-approved sermorelin product; what’s sold is compounded or research-grade, used off-label, and WADA-prohibited in sport.
Technical & analytical reference (chemistry & QC)
Molecular identity verified against PubChem (2026-06-21). Analytical-method detail below is compiled from a third-party technical reference (PeptideBiologix) and tagged where the underlying figure is uncited.
| Field | Value |
|---|---|
| Molecular formula | C149H246N44O42S |
| Average MW | 3357.93 g/mol (free base) |
| CAS | 86168-78-7 |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (GHRH 1-29-NH2) |
| HPLC purity criterion | RP-HPLC (C18, 214/280 nm), main-peak ≥95% for research-grade; preparative cut at >95% |
| MS identity | ESI-MS / MALDI-TOF; deconvoluted mass 3357.93 Da (free base), 3367.96 Da (acetate salt) |
| Counterion / net peptide | Acetate salt; peptide content by AAA/UV; acetate ≤ spec by ion chromatography |
| Storage / reconstitution | Lyophilized −20°C desiccated (24–36 mo); reconstitute in bacteriostatic or sterile water, store 2–8°C, use within ~14–28 days; buffered pH 5.0–7.0 most stable |
| Degradation / stability | Met27 oxidation (→ sulfoxide/sulfone) is the dominant pathway; Asn8/Gln16/Gln24 deamidation; Asp-X (Asp3, Asp25) peptide-bond hydrolysis; C-terminal amide loss. Optimal storage pH ~5.0–6.0 minimizes deamidation/hydrolysis |
Primary-literature citation leads (PeptideBiologix; confirm before citing): Thorner et al. 1984; Ceda et al. 1986; Corpas et al. 1992; Bowers et al. 1990; Vittone et al. 1997; Blackman et al. 2002 (named in the monograph without PMIDs/DOIs)
Sources
- Chen RG, et al. GH vs GHRH(1-29) in GH-deficient children — RCT. Acta Paediatr Suppl. 1993. : 8329830
- Neyzi O, et al. Growth response to GHRH(1-29) vs GH — RCT. Acta Paediatr Suppl. 1993. : 8329826
- Thorner M, et al. Once-daily SC GHRH accelerates growth in GHD children (Geref Intl). J Clin Endocrinol Metab. 1996. : 8772599
- Prakash A, Goa KL. Sermorelin: review (Geref dossier). BioDrugs. 1999. : 18031173
- Sigalos JT, et al. GH secretagogue (incl. sermorelin) raises IGF-1 in hypogonadal men. Am J Mens Health. 2017. : 28830317
- Muñoz-Moreno L, et al. GHRH transforms prostate epithelial cells (RWPE-1) / xenograft. Prostate. 2022. : 35322894
- Sinha DK, et al. GH secretagogues in hypogonadal males — review. Transl Androl Urol. 2020. : 32257855
- Rudman D, et al. Effects of human growth hormone in men over 60 (foundational GH body-comp RCT). N Engl J Med. 1990. : 2355952
- Brioche T, et al. GH replacement prevents sarcopenia + mitochondrial biogenesis (rat). J Gerontol A Biol Sci Med Sci. 2014. : 24300031
- Wikipedia — Sermorelin (half-life, Geref history). https://en.wikipedia.org/wiki/Sermorelin 10a. FDA. Determination that GEREF (sermorelin acetate) injection was not withdrawn for reasons of safety or effectiveness. Federal Register 78 FR 14122, Mar 4 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/
- Dosing/reconstitution cheat sheet (one practitioner).
See also: CJC-1295, Ipamorelin, CJC-1295 / Ipamorelin, Tesamorelin.
Sources & references
- Chen RG, et al. GH vs GHRH(1-29) in GH-deficient children — RCT. Acta Paediatr Suppl. 1993. : 8329830
- Neyzi O, et al. Growth response to GHRH(1-29) vs GH — RCT. Acta Paediatr Suppl. 1993. : 8329826
- Thorner M, et al. Once-daily SC GHRH accelerates growth in GHD children (Geref Intl). J Clin Endocrinol Metab. 1996. : 8772599
- Prakash A, Goa KL. Sermorelin: review (Geref dossier). BioDrugs. 1999. : 18031173
- Sigalos JT, et al. GH secretagogue (incl. sermorelin) raises IGF-1 in hypogonadal men. Am J Mens Health. 2017. : 28830317
- Muñoz-Moreno L, et al. GHRH transforms prostate epithelial cells (RWPE-1) / xenograft. Prostate. 2022. : 35322894
- Sinha DK, et al. GH secretagogues in hypogonadal males — review. Transl Androl Urol. 2020. : 32257855
- Rudman D, et al. Effects of human growth hormone in men over 60 (foundational GH body-comp RCT). N Engl J Med. 1990. : 2355952
- Brioche T, et al. GH replacement prevents sarcopenia + mitochondrial biogenesis (rat). J Gerontol A Biol Sci Med Sci. 2014. : 24300031
- Wikipedia — Sermorelin (half-life, Geref history). https://en.wikipedia.org/wiki/Sermorelin 10a. FDA. Determination that GEREF (sermorelin acetate) injection was not withdrawn for reasons of safety or effectiveness. Federal Register 78 FR 14122, Mar 4 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/
- Dosing/reconstitution cheat sheet (one practitioner).
See also: CJC-1295, Ipamorelin, CJC-1295 / Ipamorelin, Tesamorelin.
Community experience reports
Anecdotal — real-world reports from the peptide community, not clinical evidence. Presented alongside the graded science above, not as a substitute for it.
Companion raw digest: Evidence tier: throughout Last updated: 2026-07-10 Cross-refs:
*cjc-1295-no-dac*·[CJC-1295 / Ipamorelin](/peptides/cjc-1295-ipamorelin/)·[Ipamorelin](/peptides/ipamorelin/)·[Tesamorelin](/peptides/tesamorelin/)
Who reports the strongest results
Older adults seeking conservative, clinically-supervised GH optimization — the population sermorelin was originally designed for. The community’s 59-year-old (arc_tickat) who eliminated love handles and described “10 years of youth returned to energy” after 12 clinic-monitored weeks is the archetype. Sermorelin’s track record, regulatory history, and physician-overseen availability make it the preferred choice for this group.
The honest community placement
Sermorelin is the oldest and most clinically established GHRH analogue, but it is also the weakest. Community is candid about this:
- It works — GH pulse stimulation is real, IGF-1 rises are documented
- It works more slowly and less dramatically than CJC-1295 + Ipamorelin
- The trade-off is legitimate: longer regulatory track record, physician oversight more available, lower risk of unexpected effects
- Community consensus: “If you want the safest, most research-backed option with the longest history, sermorelin. If you want the best results per injection, upgrade to CJC-1295 + ipamorelin.”
What community reports across time
Weeks 1–2: Sleep first
Same early signal as every GH peptide: deeper sleep, vivid dreams, improved morning energy.
Weeks 4–12+: Body composition (slower timeline)
Body composition changes at weeks 6–12, later and more gradual than CJC-1295 protocols.
The gene_Devine 8-month log: The most detailed community record — continuous sermorelin use for 8 months with labs. IGF-1 increased moderately; fat loss occurred cumulatively over months rather than dramatically; energy and recovery improved from months 2–3. Conclusion: “It works, just slowly and mildly. The risk profile justifies it for cautious users.”
The almsgt non-response account: IGF-1 baseline 108 → 138 ng/mL after 12 weeks (+28%). Technically a response; functionally felt like nothing. Community interpretation: at a significantly depleted baseline, sermorelin’s dose-limited GH pulses may not be enough to produce felt benefit. The recommendation from this thread: if minimal IGF-1 response at 12 weeks, upgrade to CJC-1295 + ipamorelin.
Protocol as used by the community
Dose: 200–500 mcg SubQ, pre-sleep (primary dose window)
Combination with ipamorelin: Standard practice — ipamorelin amplifies the GH pulse that sermorelin triggers. Solo sermorelin is effective but weaker than the combination.
Cycling: 12–24 weeks in clinical anti-aging settings; 12 weeks on / 4–8 weeks off in community self-experimentation.
Clinic vs research-grade sourcing: Sermorelin is the GH peptide most associated with physician-supervised anti-aging practice. Community preference for clinic sourcing is stronger here than for any other GH peptide.
Side effects
Very mild profile; best-tolerated of the GH peptides.
- Water retention: mild; less than CJC-1295 at equivalent effect levels
- Headache: occasional
- Tingling in extremities: less frequent than CJC-1295
- Carpal tunnel: At higher doses or prolonged use — one documented case (Vince Carter account) of discontinuation due to functional impairment; reversed after stopping. Flag at higher doses.
Frequently asked questions
Sermorelin vs CJC-1295 — which should I use? For physician-supervised use or maximum safety track record: sermorelin. For maximum effect per cycle: CJC-1295 + ipamorelin. Not mutually exclusive — some users start with sermorelin at a clinic and transition to CJC protocols.
Why is my IGF-1 not moving? Sermorelin has a lower ceiling on GH pulse amplitude than CJC-1295. At significantly depleted baselines, the pulse may not be strong enough to produce large IGF-1 changes. Consider upgrade or dose increase with physician guidance.
Cross-references
*cjc-1295-no-dac*— the stronger GHRH alternative[CJC-1295 / Ipamorelin](/peptides/cjc-1295-ipamorelin/)— the combination most community members eventually use[Ipamorelin](/peptides/ipamorelin/)— the standard GHRP pairing for sermorelin[Tesamorelin](/peptides/tesamorelin/)— the GHRH specialist for visceral fat